Engineered Biomimetic Copper Sulfide Nanozyme Mediates "Don't Eat Me" Signaling for Photothermal and Chemodynamic Precision Therapies of Breast Cancer

ACS Appl Mater Interfaces. 2023 May 24;15(20):24071-24083. doi: 10.1021/acsami.3c01047. Epub 2023 May 9.

Abstract

The rapid development of nanomedicine has brought hope and confidence to the precise treatment of tumors. However, the efficacy of nanoparticle-mediated therapy is severely limited due to phagocytosis and clearance by macrophages. CD47 is a well-documented ″don't eat me″ signaling molecule that binds to the SIRPα receptor on the macrophage surface, inhibiting the phagocytic behavior of the macrophages. In this study, CD47-overexpressing cancer cell membranes were used to coat hollow copper sulfide nanoparticles. The nanoparticles were shown to have an extended circulatory half-life and to actively target breast cancer, leading to increased accumulation in the tumor tissue. An excellent photothermal therapeutic effect was produced by near-infrared laser irradiation. At the same time, β-lapachone within the nanoparticles generated large amounts of hydrogen peroxide in the tumor environment, which was then catalyzed by the copper sulfide nanozyme to cytotoxic hydroxyl radicals, exerting a chemodynamic therapeutic effect. This engineered biomimetic nanozyme, through the mediation of the ″don't eat me″ signal, achieved both photothermal and chemodynamic precision treatments of breast cancer, creating a new mode of safe and effective tumor treatment.

Keywords: CD47; cancer cell membrane; chemodynamic therapy; nanozyme; photothermal therapy.

MeSH terms

  • Biomimetics
  • Breast Neoplasms* / pathology
  • CD47 Antigen / metabolism
  • Copper / metabolism
  • Female
  • Humans
  • Macrophages / metabolism
  • Neoplasms* / drug therapy
  • Phagocytosis

Substances

  • CD47 Antigen
  • Copper